Cannabinoids and Traumatic Brain Injury: A Randomized, Placebo Controlled Trial

Primary Objective

This is a double-blind, placebo-controlled, parallel group study designed to assess the tolerability and efficacy of fsCBD and bsCBD, compared to a placebo control, to improve cognition and traumatic brain injury-related symptoms. If eligible for the study, subjects will be randomized to receive one of the conditions for 12 weeks.

Is this Study for You?

Let's Get Started!

Description

If eligible for the study, subjects will be randomized to receive one of the conditions for 12 weeks.

Details
Age

Adult

Type of Study

Treatment

Scope

Local

Locations

Department Specific Free Standing Clinic
Outpatient CTRC
University of Colorado Hospital

Principal Investigator
Photograph of Kent Hutchison,  PhD

Kent Hutchison, PhD

Study ID

Protocol Number: 22-1427

More information available at ClinicalTrials.gov: NCT05632627

Is this Study for You?

Let's Get Started!

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers